September 2020 Report

New and First Time
Generic Drug Report

New Brand Drug Pipeline

Medication (Brand name) Drug Class Therapeutic Use Status Update
Tramadol Oral Solution (Qdolo™) Opioid Agonist Pain Launch pending. Approved September 1, 2020.
Oliceridine (Olinvyk™) Injection Opioid Agonist Pain Launch anticipated following DEA assigning controlled substance schedule. Approved August 7, 2020.
Metoclopramide Nasal Spray (Gimoti™) Gastrointestinal Agent Gastroparesis Launch anticipated Q4 2020. Approved June 19, 2020.
Celecoxib Oral Liquid (Elyxyb™) NSAID Migraine Headache Treatment Launch pending. Approved May 5, 2020.
Benzhydrocodone HCl/
Acetaminophen
(Apadaz™)
Opioid Analgesic –
Immediate Release
Pain Launch pending. Approved February 23, 2018.
Buprenorphine Depot
Injection
(Brixadi™)
Opioid Agonist Treatment of
Opioid Addiction
Anticipated approval December 1, 2020 following
expiration of exclusivity period for Sublocade™.
Zolmitriptan (Qtrypta™) Patch Migraine Agent Migraine Headache Treatment FDA review anticipated October 2020.
Celecoxib/Tramadol NSAID/Opioid Agonist Pain FDA review pending.
Ansofaxine Antidepressant Major Depressive Disorder FDA review anticipated December 2020.
Naloxone Injection (Zimhi™) Opioid Antagonist Opioid Overdose FDA declined to approve November 2019.

Generic Pipeline

Medication (Brand name) Drug Class Therapeutic Use Status Update
Apixaban (Eliquis®) Anticoagulant Treatment/Prophylaxis of Deep Vein Thrombosis Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years.
Naloxone HCl
(Narcan®) Nasal Spray
Opioid Antidote Opioid Overdose Launch pending. Generic approved April 19, 2019.
Emtricitabine/Trenofovir
(Truvada®)
Antiretroviral HIV Post-Exposure Prophylaxis Generic anticipated late 2020.

Available in the Last 12 Months

Medication (Brand name) Drug Class Therapeutic Use Status Update
Rimegepant (Nurtec™ ODT) CGRP Antagonist Migraine Headache Treatment March 2020
Ubrogepant (Ubrelvy™) CGRP Antagonist Migraine Headache Treatment March 2020
Lasmiditan (Reyvow™) Migraine Agent Migraine Headache Treatment January 2020
Sumatriptan Nasal Spray (Tosymra™) Migraine Agent Migraine Headache Treatment October 2019

Newly Available Generics

Medication (Brand name) Drug Class Therapeutic Use Status Update
Albuterol Sulfate (Proventil® HFA) Inhaled Bronchodilator Asthma April 2020
Naproxen/Esomeprazole (Vimovo®) NSAID/GI Protectant Pain/Stomach Ulcer Prophylaxis February 2020
Albuterol Sulfate (ProAir® HFA) Inhaled Bronchodilator Asthma February 2020
Hydrocodone Bitartrate (Zohydro® ER) Opioid Analgesic – Extended Release Pain January 2020
Doxepin (Silenor®) Tricyclic Antidepressant Sleep Disorders January 2020

Discontinuations

Medication (Brand name) Drug Class Therapeutic Use Status Update
Ranitidine (Zantac®) H-2 Receptor Antagonist Heartburn/Stomach Ulcer Prophylaxis FDA asked all manufacturers to remove product from the market on April 1, 2020.
Morphine Sulfate/Naltrexone HCl (Embeda®) Opioid Analgesic – Extended Release Abuse Deterrent Pain Stop sale date November 15, 2019 with anticipated unavailability early 2020.
  • Stay Informed - Subscribe Today

  • This field is for validation purposes and should be left unchanged.